A detailed history of Kempen Capital Management N.V. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Kempen Capital Management N.V. holds 5,318 shares of REGN stock, worth $3.79 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
5,318
Previous 6,272 15.21%
Holding current value
$3.79 Million
Previous $6.59 Million 42.55%
% of portfolio
0.04%
Previous 0.07%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025

SELL
$701.85 - $1046.91 $669,564 - $998,752
-954 Reduced 15.21%
5,318 $3.79 Million
Q3 2024

Nov 14, 2024

SELL
$1024.09 - $1201.76 $1.34 Million - $1.58 Million
-1,313 Reduced 17.31%
6,272 $6.59 Million
Q2 2024

Jul 24, 2024

BUY
$883.2 - $1071.19 $846,105 - $1.03 Million
958 Added 14.46%
7,585 $7.97 Million
Q1 2024

May 14, 2024

BUY
$902.69 - $993.35 $1.37 Million - $1.51 Million
1,520 Added 29.76%
6,627 $6.38 Million
Q4 2023

Feb 14, 2024

BUY
$775.18 - $881.7 $210,848 - $239,822
272 Added 5.63%
5,107 $4.49 Million
Q3 2023

Nov 14, 2023

BUY
$692.45 - $844.37 $279,057 - $340,281
403 Added 9.09%
4,835 $3.98 Million
Q2 2023

Aug 14, 2023

BUY
$700.03 - $830.35 $95,204 - $112,927
136 Added 3.17%
4,432 $3.18 Million
Q1 2023

May 12, 2023

BUY
$680.49 - $826.97 $163,317 - $198,472
240 Added 5.92%
4,296 $3.53 Million
Q4 2022

Feb 14, 2023

BUY
$705.89 - $766.39 $289,414 - $314,219
410 Added 11.25%
4,056 $2.93 Million
Q3 2022

Nov 14, 2022

SELL
$573.97 - $724.32 $326,014 - $411,413
-568 Reduced 13.48%
3,646 $2.51 Million
Q2 2022

Aug 15, 2022

BUY
$548.35 - $738.84 $93,219 - $125,602
170 Added 4.2%
4,214 $2.49 Million
Q1 2022

May 13, 2022

BUY
$595.12 - $698.43 $2.41 Million - $2.82 Million
4,044 New
4,044 $2.82 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $76.5B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Kempen Capital Management N.V. Portfolio

Follow Kempen Capital Management N.V. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kempen Capital Management N.V., based on Form 13F filings with the SEC.

News

Stay updated on Kempen Capital Management N.V. with notifications on news.